Measurable residual disease testing for personalized treatment of acute myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Measurable residual disease testing for personalized treatment of acute myeloid leukemia

Published:2019-03-28 Issue:5 Volume:127 Page:337-351
ISSN:0903-4641
Container-title:APMIS
language:en
Short-container-title:APMIS

Author:

Ehinger Mats¹,Pettersson Louise²³

Affiliation:

1. Department of Clinical Sciences, Pathology Skane University Hospital, Lund University Lund Sweden

2. Department of Pathology Halland Hospital Halmstad Region Halland Halmstad Sweden

3. Faculty of Medicine Division of Pathology Department of Clinical Sciences Lund Lund University Lund Sweden

Publisher

Wiley

Subject

Microbiology (medical),General Medicine,Immunology and Allergy,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apm.12926

Reference115 articles.

1. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

2. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

3. Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

4. Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

5. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment;Blood Reviews;2023-11

2. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia;Clinical and Translational Oncology;2023-01-04

3. The mythological chimera and new era of relapse prediction post-transplant;Blood Reviews;2023-01

4. Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications;Clinical and Experimental Medicine;2022-10-13

5. Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey;Frontiers in Oncology;2022-02-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3